Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial

摘要: The combination of tamoxifen and transdermal hormone replacement therapy (HRT) may potentially reduce risks side-effects either agent, but an adverse interaction could attenuate their beneficial effects. We assessed the effects on cardiovascular risk factors within a prevention trial tamoxifen. Baseline 12-month measurements total, low-density lipoprotein (LDL)- high-density (HDL)-cholesterol, platelets white blood cells were obtained in following four groups: (n = 1117), placebo 1112), HRT 68), 87). analysis was further extended to women who at randomization discontinued it during intervention period 33 n 35 placebo) not started 36 both arms study). Compared with small changes group, associated LDL- HDL-cholesterol approximately -9%, -19% +0.2% continuous users compared -14% -0.8% never users. Similarly, there no platelet count. In contrast, decrease total LDL-cholesterol levels induced by blunted two-thirds while (P 0.051 for term). conclude that are unchanged current users, whereas they be attenuated start Whereas already is warranted, prescription its activity.